Browse > Article
http://dx.doi.org/10.5487/TR.2018.34.3.191

A Collaborative Study to Establish the Second Korean National Reference Standard for Snake Venom  

Han, Kiwon (Blood Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Jung, Kikyung (Blood Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Oh, Hokyung (Blood Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Song, Hojin (Blood Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Park, Sangmi (Blood Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Kim, Ji-Hye (Blood Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Min, Garam (Blood Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Lee, Byung-Hwa (Quality Control Team, Korea Vaccine Co., Ltd.)
Nam, Hyun-sik (New Drug Development Center, Osong Medical Innovation Foundation)
Kim, Yang Jin (Department of Statistics, Sookmyung Women's University College of Science)
Ato, Manabu (Department of Immunology, National Institute of Infectious Diseases)
Jeong, Jayoung (Blood Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Ahn, Chiyoung (Advanced Therapy Products Research Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety)
Publication Information
Toxicological Research / v.34, no.3, 2018 , pp. 191-197 More about this Journal
Abstract
In 2015, a candidate for the second national reference standard (NRS) of Gloydius snake venom was produced to replace the first NRS of Gloydius snake venom. In the present study, the potencies of the candidate were determined by a collaborative study, and the qualification of the candidate was estimated. The potencies of the candidate were determined by measuring the murine lethal titers and lapine hemorrhagic titers of venom against the regional working reference standard (RWRS) for antivenom using the methods described in the previous report for the first NRS of Gloydius snake venom. Three Korean facilities contributed data from a total of 30 independent assays. Subsequently, two foreign national control research laboratories contributed to this collaborative study. The results were calculated using the Reed-Muench method for lethality and determined using a mixed-effects model for hemorrhage. The general common potencies of the lethal and hemorrhagic titers were obtained from the results of the 30 tests performed at three Korean facilities. The results are expressed in micrograms for 1 test dose (TD) with a 95% confidence interval as follows: a lethal titer of $90.13{\mu}g/TD$ (95% confidence interval = $87.39{\sim}92.86{\mu}g$) and a hemorrhagic titer of $10.80{\mu}g/TD$ (95% confidence interval = $10.46{\sim}11.14{\mu}g$). In addition, the candidate preparation showed good quality evaluation according to the results of the quality estimation of the candidate and is judged to be suitable to serve as the Korean NRS for snake venom. In conclusion, the second NRS of Gloydius snake venom was established in this study and will be used for national quality control, including a national lot release test of Korean antivenom products.
Keywords
National reference standard; Collaborative study; Gloydius snake venom; Lethal titer; Hemorrhagic titer;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Wuster, W., Golay, P. and Warrell, D. (1997) Synopsis of recent developments in venomous snake systematics. Toxicon, 35, 319-340.   DOI
2 Lim, H., Kang, H.G. and Kim, K.H. (2013) Antivenom for snake bite in Korea. J. Korean Med. Assoc., 56, 1091-1103.   DOI
3 Eble, J.A. (2010) Matrix biology meets toxinology. Matrix Biol., 29, 239-247.   DOI
4 Omori, T., Iwanaga, S. and Suzuki, T. (1964) The relationship between the hemorrhagic and lethal of Japanese mamushi (Agkistrodon halys blomhoffi) venom. Toxicon, 2, 1-4.   DOI
5 Korea Food and Drug Administration (1993) Minimum Requirement for Biological Products (in Korean).
6 Fukuda, T., Iwaki, M., Hong, S.H., Oh, H.J., Wei, Z., Moro- kuma, K., Ohkuma, K., Dianliang, L., Arakawa, Y. and Takahashi M. (2006) Standardization of regional reference for mamushi (Gloydius blomhoffii) antivenom in Japan, Korea, and China. Jpn. J. Infect. Dis., 59, 20-24.
7 Yoo, S.H., Lee, N.K., Kim, S.N., Hong, C.M., Lee, K.H., Shin, I.S., Lim, J.H., Kim, Y.L., Ahn, M.J. and Park, S. (2004) Establishment of venom standard for potency test of Agkistrodon antivenom. The Annual Report of KFDA, 8-1, 1031-1036.
8 Oh, H., Shin, J., Ato, M., Ma, X., Williams, D., Han, K., Kim, Y.J., Kang, H.G., Jung, K., Hanada, K., Ochiai, M., Hung, P.V., Park, S. and Ahn, C. (2017) The First Meeting of the National Control Laboratories for Vaccines and Biologicals in the Western Pacific in 2016. Osong Public Health Res. Perspect., 8, 91-103.   DOI
9 Reed, L.J. and Muench, H. (1938) A simple method of estimating fifty percent endpoints. Am. J. Epidemiol., 27, 493-497.   DOI
10 Kondo, H., Kondo, S., Sadahiro, S., Yamauchi, K. and Murata, R. (1971) Standardazation of trimeresurus flavoviridis (Habu) antivenin. J. Med. Sci. Biol., 24, 323-327.   DOI
11 World Health Organization (2010) WHO guidelines for the production control and regulation of snake antivenom immunoglobulins. World Health Organization, Geneva. [cited 2017 Jan 1]. Available from: http://www.who.int/bloodproducts/snake_antivenoms/snakeantivenomguide/en/.
12 Lee, N., Seo, J.S., Kim, J.O. and Ban, S.J. (2017) Establishment of the 2nd Korean national biological reference standard for blood coagulation factor VIII:C concentrate. Biologicals, 47, 59-63.   DOI
13 ICH (1995) Quality of biotechnological products: stability testing of biotechnological/products: stability testing of biotechnological/biological products. Q5C in International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.